A multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria.

As of 2018, cryptococcal antigen (CrAg) screening in patients with advanced human immunodeficiency virus (HIV) disease (AHD) was not routinely implemented in Nigeria despite being recommended in the national HIV treatment guidelines. Our aim was to determine the prevalence and risk factors for asymptomatic cryptococcal antigenemia in adult people living with HIV (PLHIV) in Nigeria to advocate for the implementation of routine CrAg screening. A descriptive cross-sectional study and CrAg screening of consecutive adult PLHIV with CD4 counts ≤200 cells/µL was conducted from April 2018 to April 2019 at HIV clinics in eleven tertiary hospitals spread across Nigeria's six geopolitical regions. Prevalence of asymptomatic cryptococcal antigenemia was estimated by facility and geopolitical zone. Logistic regression was conducted to identify risk factors for cryptococcal antigenemia. In total, 1,114 patients with AHD were screened. The overall prevalence of asymptomatic cryptococcal antigenemia was 3.9% with wide variation across facilities (range: 0/75 [0%]- 15/122 [12.3%]) and geopolitical zones (range: 0/75 [0%]-19/279 [6.8%]). Prevalence of antigenemia was highest in the South-West (19/279 [6.8%]) and lowest in the North-East (0/75 [0%]). Prevalence was 5.2% (26/512) and 3.2% (18/561) in patients with CD4<100 and CD4 of 101-200, respectively. Of all patients with antigenemia, 50% were on antiretroviral therapy (ART) at the time of having a positive CrAg test. In adjusted analysis, cryptococcal antigenemia was significantly less in patients on ART and patients who had completed any formal education. The survey showed a high overall burden of cryptococcal antigenemia in Nigeria, with variable prevalence across geopolitical regions. We provided valuable evidence for implementing routine CrAg screening of AHD patients in Nigeria which has commenced in selected centres.

Prevalence of Zika and malaria in patients with fever in secondary healthcare facilities in south-eastern Nigeria.

We describe the frequency of Zika and malaria among patients presenting with fever to secondary health facilities in Cross River State, Nigeria. Using a cross-sectional, stratified survey design, we randomly selected nine facilities and consecutively recruited 100 participants (aged ≥ 1 year) who presented with fever. On testing blood samples using Biocan qualitative lateral flow immuno-chromatographic cassettes for Zika IgG and IgM, 10% were seropositive for Zika virus (ZIKV) IgM, 12% for ZIKV IgG and 20% for ZIKV IgM, IgG or both. Following microscopy of thick films stained with Giemsa for malaria parasites, 55% were positive for malaria and 15% were positive for both malaria and ZIKV IgM, IgG or both. A moderately negative association between urban and rural household location and seropositivity for ZIKV IgM or IgG was found on logistic regression. Our results clearly indicate a high rate of probable ZIKV and malaria co-incidence in Cross River State. Given the high risk of serious fetal outcomes following ZIKV infection, further epidemiological research and surveillance systems for ZIKV are clearly required.

A cross-sectional survey on the seroprevalence of dengue fever in febrile patients attending health facilities in Cross River State, Nigeria.

BACKGROUND: In Nigeria, recent reports suggest that dengue viruses could be a major cause of acute fevers. We sought to make a cross-sectional estimate of the prevalence of current and previous dengue infections in patients presenting with fever to healthcare centres in Cross River State Nigeria. METHODOLOGY/PRINCIPAL FINDINGS: This cross-sectional health facility survey recruited persons with temperature ≥38°C. Dengue virus immunoglobulin M (IgM)/immunoglobulin G (IgG) antibody testing using Onsite Duo dengue Ag-IgG/IgM lateral flow immunoassay cassettes was done. Samples which tested positive were further confirmed using the RecombiLISA dengue IgM and IgG enzyme linked immunosorbent assay kits and classified into primary and secondary dengue infection. Malaria testing was carried out using microscopy. Between 4 January 2017 and 24 August 2017 a total of 420 participants were sampled across 11 health centres. The mean age was 34 (range = 1-99), 63% were female, 49% reported sleeping under a treated mosquito net in the past week and 44% reported taking an antimalarial prior to seeking care. The mean number of days fever was present prior to seeking care was 8, and many of the participants presented with symptoms indicative of respiratory or urinary tract infections. Testing indicated that 6% (95% CI: 2, 13; n = 24) had either a primary or secondary dengue infection with or without co-existing malaria, while 4% (95% CI: 2, 9; n = 16) had either a primary or secondary dengue infection without co-existing malaria. 52% (95% CI: 46, 58; n = 218) had a malaria infection with or without any dengue infection, and 50% (95% CI: 44, 57; n = 210) had a malaria infection without any dengue infection. CONCLUSION: Our study confirms the presence of dengue at not insignificant levels in patients attending health centres with fever in this south eastern province of Nigeria. These data highlight the danger of the common presumption in this setting that fever is due to malaria. Surveillance for dengue is vital in this setting.

Evaluation of Diagnostic Accuracy of Rapid Diagnostic Test for Malaria Diagnosis among Febrile Children in Calabar, Nigeria.

BACKGROUND: The WHO recommends that all cases of suspected malaria should undergo parasitological test. Currently, the parasitological test comprises the rapid diagnostic test (RDT) or the microscopy. The performance of RDT in relation to microscopy is yet to be fully comprehended. OBJECTIVES: This study evaluated the diagnostic accuracy of RDT as against the diagnosis provided by microscopy in detecting malaria parasites among febrile under-5 children. DESIGN: The study was a cross-sectional hospital-based design. MATERIALS AND METHODS: Capillary blood samples were collected from 167 children who came to the hospital with a history of fever over a period of 6 months. The Paracheck-Pf RDT kit was used and its performance was compared with the gold standard, microscopy using thick film. RESULTS: The prevalence of malaria infection was 41.9%. On comparing RDT with microscopy (microscopy assumed to be 100% sensitive and specific), RDT had a sensitivity of 51.4% and a specificity of 73.2%. The false-positive rate was 26.8% whereas the false-negative rate was 48.6%. The positive predictive value was 58.1% whereas the negative predictive value (NPV) was 67.6%. The RDT also had a positive likelihood ratio (LR) of 1.92 and a negative LR of 0.67. The RDT test accuracy was 64.1%. CONCLUSION: Malaria prevalence among febrile children was found to be high. The findings also suggest that inconsistencies in the performance of RDT kits may arise from many extraneous factors, and as such, they should not be used as a stand-alone test kit except a prior batch/lot validation test was carried on them.

Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, Nigeria.

OBJECTIVE/BACKGROUND: World Health Organization tuberculosis (TB) indices from 2014 to 2016 showed that Nigeria had the 6th highest prevalence, 4th highest incidence, and the highest mortality rate globally. In efforts to improve TB care, the XpertMTB/Rif (GeneXpert) technology, Cepheid, Sunnyvale, California, USA, which has revolutionized TB detection with concomitant rifampicin-resistance molecular detection, was introduced in Cross River State, South-South Nigeria, in 2014. The GeneXpert uses molecular beacons to detect five overlapping 81-bp regions in the rpoB gene known as the Rifampicin Resistant Determinant Region (RRDR). These probes are represented as Probe A (507-511), Probe B (512-518), Probe C (518-523), Probe D (523-529), and Probe E (529-533). Mutations in this region have been shown to account for about 93% of resistance to rifampicin, which is the most important drug in tuberculosis treatment. The objective of this study was to determine the frequency of rifampicin resistance and the commonly associated probes for various rpoB gene mutations within the 81-bp RRDR of Mycobacterium tuberculosis in Cross River State, Nigeria. METHOD: We collated and analyzed data from the 10 Xpert MTB/Rif sites in Cross River State from June 2014 to June 2016 and determined the frequency of mutations associated with different probes designated A-E, which represent the RRDR of rpoB gene. All centers use XpertMTB/Rif version G4. RESULT: In total, 973 tuberculosis cases were detected from 4671 cases tested. Rif resistance was detected in 6.0% (58/973) of cases. Probe E mutations were the most common, seen in 60.3% (35/58); followed by Probe D, 17.2% (10/58); and Probe B, 13.8% (8/58). Probe A occurred in 3.4% (2/58). No Probe C mutation was seen. Multiple mutation combinations involving probes B and D occurred in 3.4% (2/58), while one isolate had triple site mutations involving A, D, and E. One isolate that at initial testing showed a Probe A mutation displayed a Probe D mutation when tested in another site prior to treatment enrollment. CONCLUSION: In our setting, 6.0% of tuberculosis isolates are rifampicin resistant. Mutations associated with probe E commonly due to codon 531 are the most predominant cause of rifampicin resistance. Mutations at probe C (codons 518-523) were uncommon. A change in mutation may have occurred in one of the patients.